Litcius/Paper detail

Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study

Bridget E Barber, Melissa Fernandez, Hardik Babubhai Patel, Catalina Barcelo, Stephen D Woolley, Harilal Patel, Stacey Llewellyn, Azrin N Abd-Rahman, Sunil Sharma, Mukul Jain, Ashok Ghoghari, Ilaria Di Resta, Aline Fuchs, Ioanna Deni, Tomas Yeo, Sachel Mok, David A Fidock, Stephan Chalon, Jörg J Möhrle, Deven Parmar, James S McCarthy, Kevinkumar Kansagra

2022The Lancet Infectious Diseases36 citationsDOI

Topics & Concepts

MedicineVolunteerMalariaPharmacologyIntensive care medicineChloroquineHealth careDrugImmunologyInternal medicineDiseaseVivax malariaClinical trialProguanilPlasmodium falciparumPediatricsVirologyMalaria Research and ControlTuberculosis Research and EpidemiologySynthesis and biological activity
Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study | Litcius